AngioDynamics, Inc. (ANGO) stock analysis

Healthcare · Medical Instruments & Supplies

From the 10-K filed 2026-07-14

How it makes money

Hospitals and healthcare providers pay AngioDynamics for medical devices used in minimally invasive vascular and oncology procedures.

AngioDynamics generates revenue by designing, manufacturing, and selling specialized medical devices across two segments, Med Tech and Med Device. Professional healthcare providers, including interventional radiologists, vascular surgeons, and oncologists, utilize these products in image-guided procedures. Sales volume and hospital adoption rates drive results, as many products are single-use disposables or short-term implants.

Price realization is increasingly constrained by hospital consolidation and the growing power of group purchasing organizations and integrated health delivery networks. As buyers gain scale, pricing pressure intensifies across product lines, making contract retention and new product adoption critical variables for revenue generation.

What protects it: the moat

Proprietary technology, regulatory clearances, and patent protection form the primary barriers against competitors.

Management asserts that competitive advantages stem from innovative research and development, clinical and regulatory pathway expansion, and customer-centric sales execution. The company relies on securing patents for complex medical devices and obtaining regulatory clearances, such as FDA approvals, to enter new markets and protect its product lines from immediate imitation.

However, the medical device industry experiences rapid technological change and frequent product introductions from competitors with substantially greater resources. Consequently, patent protection and regulatory barriers represent management's claims of differentiation rather than permanent insulation against larger, better-capitalized rivals.

What growth costs

AngioDynamics reinvests capital into research and development, clinical trials, and restructuring activities to maintain and grow its product portfolio.

To sustain operations and pursue growth, the company must continuously fund complex research and development programs, market studies, and clinical trials required for regulatory approvals. Product life cycles are relatively short, demanding ongoing investment simply to keep pace with physician demand and technological obsolescence.

The business also incurs capital expenditures and restructuring costs to optimize manufacturing efficiency and capabilities. The company spent 38% of its operating cash on capital spending, reflecting the ongoing reinvestment required to support its operational footprint.

What could damage it

Loss of major group purchasing organization contracts would severely impair pricing power and revenue.

As healthcare systems and group purchasing organizations consolidate, purchasing power concentrates among fewer entities. If AngioDynamics fails to secure or retain contract positions with major group purchasing organizations and integrated health delivery networks, its products may be locked out of key hospital systems.

Losing these distribution channels would force severe price concessions or volume drops, directly eroding the revenue needed to cover high research and development expenses and leading to a permanent impairment of operating earnings.

About AngioDynamics, Inc.

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Other companies in Medical Instruments & Supplies